Photo taken from Dana-Farber News/X
Jan 28, 2024, 18:44
Interim phase 1 results show HPN328 is well tolerated and clinically active for neuroendocrine carcinomas – Dana-Farber News
Dana-Farber News recently shared a post on their X/Twitter page:
“ASCO GU24: Interim phase 1 results show HPN328, a T-cell engager, is well tolerated and clinically active for patients across a wide range of neuroendocrine carcinomas. Dana-Farber Cancer Institute’s Misha Beltran explains more here.”
Source: Dana-Farber News/X
Aug 11, 2024, 08:04
Aug 11, 2024, 07:48
Aug 11, 2024, 06:38
Aug 11, 2024, 05:36